Assessing CorMedix (CRMD) Valuation After Its Recent Share Price Momentum
CorMedix (CRMD) has quietly put together an interesting run, with the stock up about 15% over the past month and nearly 49% over the past year, catching more investor attention.
See our latest analysis for CorMedix.
That recent 4.56% 1 day share price gain, on top of a 15.15% 30 day share price return and a 48.66% one year total shareholder return, suggests momentum is quietly building as the market reassesses CorMedix’s growth and risk profile.
If CorMedix has caught your eye, this is also a good moment to explore other healthcare names by scanning healthcare stocks for fresh ideas with similar tailwinds.
With shares still trading well below analyst targets despite solid multi year returns and improving fundamentals, investors now face a key question: Is CorMedix still undervalued, or has the market already priced in its future growth?
Most Popular Narrative: 36% Undervalued
With CorMedix last closing at $12.16 against a narrative fair value of $19.00, the story behind that gap is driving growing attention.
The analysts have a consensus price target of $20.4 for CorMedix based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $23.0, and the most bearish reporting a price target of just $17.0.
Curious how aggressive revenue ramps, rising margins and a lower future earnings multiple can still point to upside from here? See which assumptions power this valuation call.
Result: Fair Value of $19 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, integration hurdles at Melinta and heavy reliance on a handful of anti infective assets could quickly undermine the upbeat growth narrative.
Find out about the key risks to this CorMedix narrative.
Build Your Own CorMedix Narrative
If you are not fully aligned with this view or prefer digging into the numbers yourself, you can quickly build a personalised narrative in just a few minutes: Do it your way
A great starting point for your CorMedix research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
Ready for more investing angles?
Before you move on, explore your next potential idea with targeted screens on Simply Wall St, or you may miss opportunities others are already acting on.
- Explore potential mispricings by running through these 875 undervalued stocks based on cash flows that highlight companies trading below what their cash flows suggest they are worth.
- Look into innovation by scanning these 25 AI penny stocks focused on businesses generating revenue from artificial intelligence.
- Support your income strategy by reviewing these 14 dividend stocks with yields > 3% that combine attractive yields with sustainable payout profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com